Efficacy and safety evaluation
asthenia, parasitemia, pain, dizziness, jaundice, skin rash, pruritus, headache, Toxicity, chills, anorexia
ADVERSE EVENT, PARASITEMIA, ANOREXIA
The WHO protocol with a 28-day follow-up to assess the therapeutic efficacy of anti-malarial drugs was used [
Follow-up schedule.Clinical efficacy was assessed by grading the pre-existing clinical signs and combining them with the temperature values. Parasitological efficacy was based on asexual parasitemia, although a gametocyte count was also systematically performed. The following clinical symptoms were assessed systematically at each visit and graded as absent, mild, moderate, severe, or very severe: perspiration, headache, chills, pain (specifying topography), jaundice, asthenia, dizziness, anorexia, skin fold, skin rash, and pruritus. The severity grading scales were adapted from guidelines provided by the WHO (Toxicity Grading Scale for Determining the Severity of Adverse Events) [